Phase I Dose-Escalation Study of the Pharmacokinetic, Safety, Tolerability, and Biologic Activity of huKS-IL-2 Administered Daily as a 1-Hour Intravenous Infusion for Five Consecutive Days for Treatment of Refractory Epithelial Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tucotuzumab celmoleukin (Primary)
- Indications Bladder cancer; Lung cancer; Renal cancer
- Focus Adverse reactions
- Sponsors EMD Serono
- 30 Oct 2013 New trial record